

PRODUCT LIST

2026





Beyond our medicines, *lives*

Our mission

Improve **patients'** lives by providing essential **medicines** focusing on **Central Nervous System** (severe pain, addiction) & **Hospital Injectables** & make a positive impact to society and the environment.



WE MAKE THE DIFFERENCE FOR PATIENTS' LIVES

Directly impacting lives: helping patients live better lives through pain management, critical care and access to essential medicines.



WE GROW RESPONSIBLY

Nurturing responsible growth: collaborating with Stakeholders for essential medicine access and advocating for the environment and social causes.



WE BUILD A SOUND & SUSTAINABLE COMPANY

Ethical commitment: prioritizing responsible and transparent business practices and investing in employee development.

Ethypharm at a glance

Ethypharm is a leading mid-size international pharmaceutical company, with strong European roots, that manufactures and provides essential medicines, with a focus on hospital care, central nervous system (severe pain and addiction) and internal medicine.

Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment.

Ethypharm has 1,900 employees dedicated to its various pharmaceutical activities, of which 1,400 are in industrial operations.


Our six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms.

With a global presence in 68 countries, the company markets its products directly in Europe and China, and has strategic partnerships in the EMEA, NA, LATAM and APAC markets.

Ethypharm works closely with the authorities and health-care professionals to ensure that its medicines are used appropriately and that patients have access to them.

To find out more about Ethypharm, visit ethypharm.com and follow us on LinkedIn.

Our Focus



Central Nervous System


Pain

Addiction



Internal Medicine

Inflammatory – Gastrointestinal – Cardiovascular Diseases



Hospital Care

Critical Care – Anesthesia – Infections

Active Ingredient	Strength	Presentation	Shelf life	Volume & Pack size	Main indication(s)	ATC code	Production
Acetylcysteine	200 mg/ml	Ampoule	2 years	10 ml	Paracetamol overdose treatment	V03AB23	UK
Aciclovir	250 mg	Lyophilized powder for solution for infusion – Vial	3 years	10 ml	Treatment & prevention of Herpes Simplex and treatment of Varicella Zoster infections	J05AB01	Spain
Adrenaline	1 mg/ml (1:1,000)	Ampoule	15 months	0.5 ml	Cardiopulmonary resuscitation. Acute anaphylaxis	C01CA24	UK
				1 ml			
				5 ml			
				10 ml			
	1 mg/10 ml (1:10,000)	Pre-filled syringe	18 months	10 ml			
Alprostadil	20 µg	Lyophilized powder for solution for infusion – Vial	2 years	8 ml	Symptomatic treatment of peripheral occlusive artery disease (PAD) in Leriche-Fontaine stages III and IV, excluding patients who are candidates for amputations	C01EA01	Spain
Aprepitant	80 mg	Capsule	4 years	Flexible	Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy	A04AD12	France
	125 mg						
	80 mg/ 125 mg						
Atosiban Acetate	37.5 mg/ 5 ml	Vial	4 years	5 ml	Delay imminent preterm birth	G02CX01	Spain
	6.75 mg/ 0.9 ml	Ampoule		0.9 ml			
Atropine Sulfate	600 µg/ml 1 mg/ml	Ampoule	3 years	1 ml	To reduce salivary and bronchial secretion. To treat bradycardia induced by drugs or toxic substances and acute myocardial infarction	A03BA01	UK
Azithromycin	500 mg	Lyophilized powder for solution for infusion – Vial		12 ml	Treatment of the infections, caused by micro-organisms sensitive to azithromycin	J01FA10	Spain

Active Ingredient	Strength	Presentation	Shelf life	Volume & Pack size	Main indication(s)	ATC code	Production
Buprenorphine Hydrochloride	2 mg	Oral lyophilizate	3 years	Flexible	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment	N07BC01	UK (Catalent)
	8 mg						
	0.4 mg	Sublingual tablet	2 years	Pack x 7	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment	N07BC51	France
	1 mg			Pack x 28			
	2 mg						
	4 mg						
	6 mg						
	8 mg						
Buprenorphine/ Naloxone	2/0.5 mg	Sublingual tablet	2 years	28 tabs per pack	Substitution treatment for opioid drug dependence	N07BC51	France
	8/2 mg						
Caffeine Citrate	10 mg/ml	Ampoule	3 years	1 ml	Treatment of apnoea of prematurity	N06BC01	UK
		Oral Solution		5 ml			
Calcium Folate Hydrate	50 mg	Lyophilized powder for solution for infusion – Vial	2 years	10 ml	Calcium folinate rescue to reduce methotrexate/ folic acid antagonist toxicity and manage overdose. In combination with 5-fluorouracil in cytotoxic therapy	V03AF03	Spain
	350 mg			20 ml			
Captopril	5 mg/5 ml	Oral solution	18 months	100 ml	Hypertension, Heart Failure, Myocardial Infarction, Type I Diabetic Nephropathy. Can be used alone and in combination with other antihypertensive agents, especially thiazide diuretics	C09AA01	UK
	25 mg/5 ml		12 months				
Cardioplegia Infusion	20 ml	Ampoule	3 years	20 ml	Used during heart surgery to induce cardioplegia	B05XA16	UK

Active Ingredient	Strength	Presentation	Shelf life	Volume & Pack size	Main indication(s)	ATC code	Production
Ciprofloxacin	2 mg/ml	Bag	18 months	100 ml 200 ml	Treatment of the infections, caused by micro-organisms sensitive to ciprofloxacin	J01MA02	Spain
Clarithromycin	500 mg	Lyophilized powder for solution for infusion – Vial	3 years	20 ml	Treatment of the infections, caused by micro-organisms sensitive to clarithromycin	J01FA09	Spain
Clobazam	5 mg/5 ml 10 mg/5 ml	Oral suspension	2 years	150 ml 250 ml	Adjuvant therapy in epilepsy. Short-term relief of severe anxiety	N05BA09	UK
Colistimethate Sodium	1 MIU 2 MIU	Lyophilized powder for solution for infusion – Vial	3 years	10 ml	Treatment of serious infections due to selected aerobic Gram-negative pathogens	J01XB01	Spain & Italy
Dexmedetomidine Hydrochloride	4 µg/ml	polypropylene bags	2 years	100 ml	Light sedation before procedures and at ICU	N05CM18	Spain
		PVC-free polyolefin bags	21 months				
	100 µg/ml	Ampoule	2 years	2 ml			
		Vial		4 ml 10 ml			
Ephedrine Hydrochloride	30 mg/ml	Ampoule	3 years	1 ml	Reversal of hypotension from spinal or epidural anaesthesia	C01CA26	UK
Esomeprazole	20 mg	Gastro-resistant capsule	2 years	Flexible	Adults & adolescents ≥12 years: GERD: treatment, symptom control and prevention of relapse. H. pylori-associated duodenal ulcer, with antibiotics. Adults only: NSAID-associated ulcer treatment and prevention. Prevention of recurrent peptic ulcer bleeding. Zollinger–Ellison syndrome	A02BC05	France
	40 mg						
Everolimus	2.5 mg	Tablet	2 years	Flexible	Advanced breast cancer	L04AA18	France
	5 mg						
	10 mg						
Fenofibrate	145 mg	Tablet	3 years	Flexible	Hyperlipidaemia	C10AB05	France

Active Ingredient	Strength	Presentation	Shelf life	Volume & Pack size	Main indication(s)	ATC code	Production
Fentanyl	67 µg	Sublingual tablet	4 years	Flexible	Breakthrough pain in opioid therapy for chronic cancer pain	N02AB03	France
	133 µg						
	267 µg						
	400 µg						
	533 µg						
	800 µg						
Fentanyl Citrate	50 µg/ml	Ampoule	3 years	2 ml	Analgesia for short surgical procedures at low doses. Analgesia with assisted ventilation at high doses. Treatment of severe pain	N01AH01	UK
			10 ml				
Glycopyrronium Bromide	200 µg/ml	Ampoule	2 years	1 ml	To reduce salivary, tracheobronchial and pharyngeal secretion	A03AB02	UK
				3 ml			
Ibuprofen	400 mg (4 mg/ml)	Bag	2 years	100 ml	Short-term symptomatic treatment of acute moderate pain	M01AE01	Spain
	600 mg (4 mg/ml)			150 ml			
Levetiracetam	100 mg/mL	Vial	3 years	5 ml	Mono- and adjunctive therapy of epilepsy	N03AX14	Italy (Alpha Sigma) + Spain CSR
Levobupivacaine Hydrochloride	2.5 mg/ml	Ampoule	3 years	10 ml	Adults: Surgical anaesthesia and epidural pain management. Paediatric ≥6 months: Analgesia (ilioinguinal/iliohypogastric block)	N01BB10	Spain
	5 mg/ml						
	7.5 mg/ml						
	1.25 mg/ml	Bag	30 months	100 ml			
				200 ml			
0.625 mg/ml	100 ml						
Levofloxacin Hemihydrate	5 mg/ml	Bag	18 months	50 ml	Treatment of the infections, caused by micro-organisms sensitive to levofloxacin	J01MA12	Spain
				100 ml			
				250 ml			

Active Ingredient	Strength	Presentation	Shelf life	Volume & Pack size	Main indication(s)	ATC code	Production
Magnesium Sulfate	0.5 g/ml	Ampoule	3 years	10 ml	Treatment of magnesium deficiency; To prevent further seizures associated with eclampsia	A12CC02	UK
	150 mg/ml		2 years		Magnesium supplementation during electrolyte re-balancing; treatment of hypomagnesaemia and treatment of acute hypokalaemia associated with hypomagnesaemia. Magnesium supplementation in parenteral nutrition. To prevent eclampsia seizures		Spain
Mesna	100 mg/ml	Ampoule	3 years	2 ml	Prevention of urothelial toxicity in patients treated with oxazaphosphorines	R05CB05	Spain
	200 mg/ml			4 ml		V03AF01	Italy
Morphine Sulfate	1 mg	Orodispersible tablet	3 years	Flexible	For the relief of severe pain	N02AA01	France
	2.5 mg						
	5 mg						
	10 mg						
	20 mg						
	30 mg						
	2 mg/1 ml	Oral Solution	3 years	100 ml	For the relief of severe pain	N02AA01	UK
				300 ml			
				500 ml			
	10 mg/ml	Ampoule		1 ml			
	20 mg/ml						
Naloxone Hydrochloride	1 mg/ml	Pre-filled syringe	3 years	2 ml	Complete or partial reversal of opioid-induced respiratory depression	V03AB15	UK


Active Ingredient	Strength	Presentation	Shelf life	Volume & Pack size	Main indication(s)	ATC code	Production
Nimodipine	0,2 µg/ml	Liquid vial	2 years	50 ml	TBC	C08CA06	SPAIN _ CMO
Noradrenaline	0,04 mg/ml	Bag	24 months	Pack 1, 10, 25	Treatment of acute hypotensive emergencies	C01CA03	Spain
	2 mg/ml	Vial	18 months				
Oxycodone Naloxone	5/2.5 mg	Prolonged-release tablets	3 years	Flexible	Severe chronic pain	N02AA55	France
	10/5 mg						
	20/10 mg						
	40/20 mg						
Oxycodone	1 mg/ml	Oral Solution	24 months	250 ml	Severe opioid-sensitive pain, such as pain from cancer	N02AA05	UK
	10 mg/ml						
Pantoprazole Sodium Sesquihydrate	40 mg	Lyophilized powder for solution for infusion – Vial	18 months	10 ml	Reflux oesophagitis; gastric and duodenal ulcer; Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions	A02BC02	Spain
Paracetamol	10 mg/ml	Solution for infusion	12 months	50 ml	Short-term treatment of moderate pain and treatment of fever	N02BE01	Spain
				100 ml			
Pethidine Hydrochloride	100 mg/2 ml	Ampoule	36 months	1 ml	Relief of moderate to severe pain. Premedication. Obstetric analgesia	N02AB02	UK
	100 mg/ml			2 ml			

Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries


Active Ingredient	Strength	Presentation	Shelf life	Volume & Pack size	Main indication(s)	ATC code	Production
Phenylephrine Hydrochloride	0.1 mg/ml	Ampoule		1 ml	Treatment of bleeding oesophageal varices	C01CA06	Italy
		Polypropylene Bag	27 months	100 ml			Spain
		PVC-free Polyolefin bags	18 months				
Ropivacaine Hydrochloride	2 mg/ml	Bag	18 months	100 ml	Acute pain treatment	N01BB09	Spain
				200 ml			
Sodium Valproate	400 mg	Lyophilized powder for solution for infusion – Vial	2 years	20 ml	Mono- and adjunctive therapy of epilepsy	N03AG01	Spain
		Ampoule		4 ml			
Suxamethonium Chloride	50 mg/ml	Ampoule	18 months	2 ml	Muscle relaxation during general anaesthesia	M03AB01	UK
Teicoplanin	200 mg	Lyophilized powder for solution for infusion – Vial	30 months	10 ml	Treatment of the infections, caused by microorganisms sensitive to teicoplanin	J01XA02	Spain
	400 mg			4 ml			
Terlipressin Acetate	1 mg	Ampoule	18 months	10 ml	Treatment of bleeding oesophageal varices	H01BA04	Spain
Tirofiban	50 µg/ml	Bag	30 months	250 ml	Prevention of early myocardial infarction	B01AC17	Spain
Tobramycin	300 mg/ 5 ml	Plastic Ampoule	5 years	5 ml	Chronic pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis	J01GB01	Germany

Active Ingredient	Strength	Presentation	Shelf life	Volume & Pack size	Main indication(s)	ATC code	Production
Triamcinolone Hexacetonide	20 mg/ml	Ampoule	3 years	2 ml	Indicated for intra-articular treatment of inflammatory arthritis, including juvenile idiopathic arthritis (≥1 year), and acute osteoarthritis flares	H02AB08	Italy CMO
		Vials	On going	2 ml	Intra-articular or soft-tissue use as short-term adjunctive therapy in acute gouty arthritis, bursitis, tenosynovitis, epicondylitis, rheumatoid arthritis, and osteoarthritis-associated synovitis		Italy CMO
Zoledronic Acid	4 mg/5 ml	Vial	30 months	100 ml	Prevention of skeletal-related events (pathologic fractures, spinal cord compression, radiation or bone surgery, or tumor-induced hypercalcemia) in adult patients with advanced bone-involved neoplasms.	M05BA08	Spain/Italy
	4 mg/100 ml	Bag	3 years	5 ml	Treatment of adult patients with tumor-induced hypercalcemia (HIT)		Spain
	5 mg/100 ml	Bag			Osteoporosis; glucocorticoid-induced osteoporosis; Paget's disease of bone		

By your side, worldwide.



Ethypharm Group key figures



Source: Company Materials
(1) Molecules with Sales in 2025B (2) Excludes CDMO customers' MAs (3) Includes both local and central sales and marketing teams (4) QoE adjusted as per FVDD report

Notes

Beyond our medicines, *lives*

Follow us!



194 Bureaux de la Colline
Bâtiment D – 12ème étage
92213 Saint-Cloud Cedex
France

Phone: +33 (0) 1 41 12 17 20

Find out more about Ethypharm:

ethypharm.com

